Bio-Path Holdings (BPTH)
(Delayed Data from NSDQ)
$2.81 USD
+0.05 (1.81%)
Updated May 9, 2024 04:00 PM ET
After-Market: $2.77 -0.04 (-1.42%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Bio-Path Holdings, Inc. [BPTH]
Reports for Purchase
Showing records 1 - 20 ( 118 total )
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
BP1002 Phase 1/1b AML Trial Second Dose Cohort Successfully Completed
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Business Update Includes Developing Prexigebersen For Obesity
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Safely Completes BP1002 Phase 1/1b Dose Cohort 1 in Rel/Ref AML
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
3Q23: Prex AML Cohorts 1 2 Show Positive Data, Prex-A Data In Early 2024
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
2Q23: Prex AML Cohorts 1 2 Yield Positive Data, Prex-A Cohort 1 Finished
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Prex AML Cohorts 1 2 Yield Positive Data, Prex-A Cohort 1 Finished
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
1Q23: Catalyst Rich 2023, Manufacturing Challenges Are In The Past
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
4Q22: Manufacturing Back On Track Brings Clinical Catalyst Rich 2023
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Gives Broad Company Update, Several Meaningful Clinical Catalysts in 2023
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Phase 1/1b Solid Tumor Trial Starts Patient Dosing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Phase 1/1b BP1001A Trial Doses First Patient Right On Schedule
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
3Q22: Expecting Clinical Newsflow to Pick Up Next Year, Funded Into 4Q23
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J